Revascularization Outcomes in Patients With Acute Limb Ischemia and Active Neoplastic Disease

Abstract

Purpose

To report the outcomes of surgical (ST), endovascular (ET), and hybrid (HT) treatment in cancer patients with acute limb ischemia (ALI).

Materials and Methods

A multicenter retrospective registry collected 139 patients (mean age 72.3±12.4 years; 73 men) with ALI and active malignancy treated by ET (41, 29%), ST (70, 51%), or HT (28, 20%) in 7 European centers between July 2007 and February 2019. In 22 cases (16%) ALI was the first manifestation of the malignancy. Lung cancer was the most common diagnosis (38, 27%). The primary composite outcome was amputation-free survival (AFS). Overall survival, amputation-free time (AFT), and reintervention-free time (RFT) were also assessed. Cox regression analysis was applied to identify independent risk factors for the primary and secondary outcomes. Results are presented as the hazard ratio (HR) and 95% confidence intervals (CIs).

Results

ET was associated with improved 12-month AFS compared with both ST (HR 2.27, 95% CI 1.20 to 4.28, p=0.002) and HT (HR 2.14, 95% CI 1.09 to 4.18, p=0.008). ST (HR 2.50, 95% CI 1.19 to 5.53, p=0.003) and HT (HR 3.10, 95% CI 1.45 to 6.65, p<0.001) were related to an increased risk for mortality compared with ET. At 12 months, the AFT was similar between the 3 groups (ET vs ST: HR 1.52, 95% CI 0.51 to 4.53, p=0.45 and ET vs HT: HR 1.21, 95% CI 0.36 to 4.11, p=0.73). The 12-month RFT also did not differ significantly between the 3 treatment options (ET vs ST: HR 1.10, 95% CI 0.49 to 2.46, p=0.79 and ET vs HT: HR 0.51, 95% CI 0.22 to 1.17, p=0.19). ST and/or HT increased the risk for the major amputation and/or death (HR 1.76, 95% CI 1.05 to 2.05, p=0.03), while Rutherford class I ischemia (HR 0.12, 95% CI 0.02 to 0.90, p=0.04) and previous vascular interventions on the index limb (HR 0.55, 95% CI 0.32 to 0.97, p=0.04) showed a protective effect.

Conclusion

In patients with ALI and active malignant disease, ET was associated with increased AFS and overall survival compared with both ST and HT, while the limb salvage and reintervention rates were comparable among the 3 groups.

Keywords

acute limb ischemia amputation cancer endovascular therapy hybrid therapy malignancy revascularization surgery

Get full access to this article

View all access options for this article.

References

GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210.

Fitzmaurice

Dicker

, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–527.

Ferlay

Colombet

Soerjomataram

, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–387.

Mosarla

Vaduganathan

Qamar

, et al. Anticoagulation strategies in patients with cancer: JACC review topic of the week. J Am Coll Cardiol. 2019;73:1336–1349.

Navi

Reiner

Kamel

, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926–938.

Navi

Reiner

Kamel

, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood. 2019;133:781–789.

Brenner

Bikdeli

Tzoran

, et al. Arterial ischemic events are a major complication in cancer patients with venous thromboembolism. Am J Med. 2018;131:1095–1103.

Sanon

Lenihan

Mouhayar

Peripheral arterial ischemic events in cancer patients. Vasc Med. 2011;16:119–130.

Björck

Earnshaw

Acosta

, et al. European Society of Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischemia. Eur J Vasc Endovasc Surg. 2020;59:173–218.

10.

Rutherford

Baker

Ernst

, et al. Recommended standards for reports dealing with lower limb extremity ischemia: revised revision. J Vasc Surg. 1997;26:517–538.

11.

Lopes

Jorge

The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J. 2013;6:8–11.

12.

Prouse

Langner

Plomondon

, et al. Temporal trends in the management and clinical outcomes of lower extremity arterial thromboembolism within a national veteran population. Vasc Med. 2019;24:41–49.

13.

Di Nisio

Ferrante

Feragalli

, et al. Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thromb Res. 2011;127:382–383.

14.

Tuzovic

Herrmann

Iliescu

, et al. Arterial thrombosis in patients with cancer. Curr Treat Options Cardiovasc Med. 2018;20:40.

15.

Aronson

Brenner

Arterial thrombosis and cancer. Thromb Res. 2018;164(suppl 1):S23–S28.

16.

Tsang

Naughton

O’Donnell

, et al. Acute limb ischemia in patients with cancer: Should we surgically intervene? Ann Vasc Surg. 2011;25:954–960.

17.

Ouriel

Shortell

DeWeese

, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg. 1994;19:1021–1030.

18.

Javid

Magee

Galland

RB.

Arterial thrombosis associated with malignant disease. Eur J Vasc Endovasc Surg. 2008;35:84–87.

19.

Veenstra

van der Laan

Zeebregts

, et al. A systematic review and meta-analysis of endovascular and surgical revascularization techniques in acute limb ischemia. J Vasc Surg. 2020;71:654–668.e3.